Form 4: NewAmsterdam Pharma COO Acquires 44,000 Restricted Stock Units

NewAmsterdam Pharma's Chief Operating Officer, Douglas F. Kling, was granted 44,000 restricted stock units on January 7, 2025.

Summary

• Douglas F. Kling, the Chief Operating Officer of NewAmsterdam Pharma Co N.V., acquired 44,000 restricted stock units (RSUs) on January 7, 2025.
• These RSUs represent a contingent right to receive one ordinary share each.
• The RSUs will vest in three equal installments, with one-third vesting on each of the first, second, and third anniversaries of the vesting start date.
• Vesting is contingent upon Mr. Kling's continued service with the company through each vesting date.
• The RSUs were granted without any consideration.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of RSUs to the COO aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the COO.

Risks

• The vesting of the RSUs is contingent on continued employment, which could be a risk if the COO leaves the company before all RSUs vest.

Industry Context

This type of equity compensation is common practice for aligning management interests with shareholder value in publicly traded companies.

Comparison to Industry Standards

• Granting restricted stock units to key executives is a standard practice in the pharmaceutical industry, similar to companies like Amgen, Regeneron, and Gilead Sciences.
• The three-year vesting schedule is also a common approach to ensure long-term commitment from executives.

Stakeholder Impact

• The RSU grant aligns the COO's interests with those of shareholders, potentially leading to increased focus on long-term value creation.

Key Dates

Keywords

restricted stock units, RSU, equity compensation, insider transaction, NewAmsterdam Pharma, Douglas F. Kling, COO, vesting